Serum copper and zinc levels in melanoma patients.
Serum copper levels (SCL) and serum zinc levels (SZL) were evaluated in malignant melanoma patients at various clinical stages. Copper levels were generally found to be elevated, reflecting the degree and extent of tumor activity. Zinc levels and, hence, SCL:SZL ratios did not reflect tumor activity. SCL appeared to prognosticate disease progression in that all patients whose values never declined below 150 micrograms/100 ml died during the course of the study. However, not all patients who died from tumor metastases displayed persistent elevations of SCL. Patients receiving BCG immunotherapy appeared to have higher SCL than untreated patients.
D000328:Adult; D000704:Analysis of Variance; D001500:BCG Vaccine / Q000627:therapeutic use; D003300:Copper / Q000097:blood*; D005260:Female; D006801:Humans; D007978:Levamisole / Q000627:therapeutic use; D008545:Melanoma / Q000097:blood* / Q000628:therapy; D008875:Middle Aged; D009367:Neoplasm Staging; D010865:Pilot Projects; D011379:Prognosis; D015032:Zinc / Q000097:blood*
D001500:BCG Vaccine; D007978:Levamisole; D003300:Copper; D015032:Zinc